Last reviewed · How we verify
Sandimmun Neoral®, CellCept® and prednisolone — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Sandimmun Neoral®, CellCept® and prednisolone (Sandimmun Neoral®, CellCept® and prednisolone) — University of Oslo School of Pharmacy.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Sandimmun Neoral®, CellCept® and prednisolone TARGET | Sandimmun Neoral®, CellCept® and prednisolone | University of Oslo School of Pharmacy | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Sandimmun Neoral®, CellCept® and prednisolone CI watch — RSS
- Sandimmun Neoral®, CellCept® and prednisolone CI watch — Atom
- Sandimmun Neoral®, CellCept® and prednisolone CI watch — JSON
- Sandimmun Neoral®, CellCept® and prednisolone alone — RSS
Cite this brief
Drug Landscape (2026). Sandimmun Neoral®, CellCept® and prednisolone — Competitive Intelligence Brief. https://druglandscape.com/ci/sandimmun-neoral-cellcept-and-prednisolone. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab